Because there is a significant association of CHODL positivity with poor clinical outcome of lung cancer patients, CHODL positivity in resected specimens could be an index that provides valuable information to physicians in applying adjuvant therapy and intensive follow-up to the patients who are likely to relapse. Since CHODL encodes a cancer-testis antigen, it may be useful for screening of 
Introduction
Lung cancer is one of the most common cause of cancer death in the world, and non-small cell lung cancer (NSCLC) accounts for nearly 80% of those cases (1, 2) . In the last two decades several newly developed cytotoxic agents including paclitaxel, docetaxel, gemcitabine, vinorelbine and irinotecan have emerged to offer multiple therapeutic choices for patients with advanced NSCLC; however, each of the new regimens can provide only modest improvements in survival and quality of life compared with traditional cisplatin-based therapies (3) .
Recently, molecular-targeted agents, including anti-EGFR or anti-VEGF monoclonal antibody, cetuximab or bevacizumab, and small molecule inhibitors of EGFR tyrosine kinase, such as gefitinib and erlotinib have been investigated in the clinical trials and/or were approved for clinical use. These agents are effective in the treatment of advanced NSCLC to a certain extent, but a proportion of patients who could receive a survival benefit is still limited (4, 5) .
Hence, new therapeutic strategies, such as the development of more selective and effective molecular-targeted agents against lung cancer are eagerly awaited.
Genome-wide cDNA microarray analysis of cancers enabled us to obtain their comprehensive gene expression profiles and to compare the gene expression levels with clinicopathological and biological information of cancers (6) . This approach is also useful to identify unknown molecules involved in the microdissection, and subsequent comparison of the data with the expression profile of 31 normal human tissues, we identified a number of potential molecular targets for cancer diagnosis, treatment, and/or choice of therapy (6) (7) (8) (9) (10) (11) . To verify the biological and clinicopathologic significance of the respective gene products, we have also been performing high-throughput screening of loss-of-function effects by means of the RNA interference technique as well as tumor tissue microarray analysis of clinical lung cancer materials . This systematic approach identified a set of molecules that appear to fall into the category of cancer-testis antigens and whose up-regulation is a frequent and important feature of the malignant nature of human cancer. These molecules identified can be regarded as potential targets for the development of highly sensitive and specific biomarkers as well as being useful in the development of small-molecular compounds, antibodies, and cancer vaccines that could have a more specific and efficient anti-cancer effect with minimal risk of adverse effects . Among them, Chondrolectin (CHODL) was commonly overexpressed in the great majority of lung cancers.
CHODL, a human ortholog of mouse chondrolectin (chodl) encodes a single-pass transmembrane protein with one carbohydrate recognition domain (CRD) of C-type lectins (42) . C-type lectin family is classified into 17 groups according to their domain architecture. They are divided into two major types; transmembrane C-type lectins and soluble ones. These lectins have a wide variety of functions at cytoplasm, cytoplasmic membrane, and extracellular space. Mouse chodl was mainly expressed in embryonic tissues, and its expression level was tightly controlled during embryonic development. Chodl transcripts were present at the stage of 7 days post-conception (dpc), and elevated up to the stage of 15 dpc, followed by decrease at the stage of 17 dpc (43) . To date, the biological function of CHODL and its activation in human cancers were not reported.
Here we report evidences that CHODL might play a significant role in lung carcinogenesis, and is a potential diagnostic and prognostic marker for lung cancer.
Research. 
Materials and Methods
Cell lines and clinical tissue samples. The human lung-cancer cell lines used in this study included five adenocarcinomas (ADCs; A549, LC319, NCI-H1373, PC14, and NCI-H1781), five squamous cell carcinomas (SCCs; LU61, NCI-H520, NCI-H1703, NCI-H2170, SK-MES-1), one large cell carcinoma (LCC; LX1), and four small cell lung cancers (SCLCs; DMS114, DMS273, SBC-3, and SBC-5). A human bronchial epithelial cell line (BEAS-2B) was used as a control (Supplementary Table S1 ). All cells were grown in monolayers in appropriate media supplemented with 10% fetal calf serum (FCS) and were maintained at 37 o C in an atmosphere of humidified air with 5% CO 2 . Primary lung cancers were obtained with informed consent along with adjacent normal lung tissue samples from patients, as described previously (7, 11) . All tumors were staged on the basis of the pTNM pathological classification of the UICC (International Union Against Cancer) (44) . Formalin-fixed primary NSCLCs and adjacent normal lung tissue samples used for immunostaining on tissue microarrays had been obtained from 295 patients undergoing curative surgery at Saitama Cancer Center (Saitama, Japan). To be eligible for this study, tumor samples were selected from patients who fulfilled all of the following criteria: (a) patients suffered from primary NSCLC with confirmed stage (only pT1 to pT3, pN0 to pN2, and pM0), (b) patients underwent curative surgery, but did not receive any preoperative treatment, (c) among them NSCLC patients with lymph node metastasis positive (pN1, pN2) tumors were treated with platinum-based adjuvant chemotherapies after surgery, whereas patients with pN0 did not receive adjuvant chemotherapies, and (d) patients whose clinical follow-up data Immunocytochemical analysis. Immunocytochemical analyses were done as previously described (13) 
Results

CHODL expression in lung cancers and normal tissues. To search for
novel target molecules for the development of therapeutic agents and/or diagnostic biomarkers for NSCLC, we first screened genes that showed more than a 5-fold higher level of expression in cancer cells than in normal cells, in more than 50% of the lung cancers analyzed by cDNA microarray. Among 27,648 genes or ESTs screened, we identified that the expression of CHODL transcript showed 5-folds or higher in 63% of NSCLCs compared with normal lung (control). Moreover, our cDNA microarray database indicated that CHODL was hardly detectable in normal tissues except testis.
Therefore, we determined to select CHODL as a good candidate for further analyses. We CHODL, but it was not detectable in CHODL-negative LC319 and BEAS-2B cells (Fig. 1C) . Furthermore, we confirmed that CHODL protein was mainly co-localized with calreticulin that was used as an ER marker (Fig. 1D) , but not co-localized with Golgi and endosome markers (data not shown). We confirmed that the positive signal by anti-CHODL antibody obtained in lung cancer A549 cells was markedly reduced by suppression of CHODL expression by siRNA against CHODL, which proved the specificity of antibody to CHODL protein ( Supplementary Fig. S1 ).
Northern blot analysis identified a 2.8-kb CHODL transcript to be highly expressed in the testis; however it was hardly detectable in other normal tissues examined ( Fig. 2A) . We subsequently examined expression of CHODL protein in five normal tissues (heart, liver, lung, kidney, and testis), as well as lung cancers using anti-CHODL antibody, and found that it was hardly detectable in the former four tissues, whereas positive CHODL staining was detected at cytoplasm of testis and lung cancer tissues (Fig. 2B) . We confirmed that the positive signal by anti-CHODL antibody obtained in lung cancer tissues was markedly diminished by preincubation of the antibody with the CHODL antigen peptide used for immunization of goat, which also independently indicated its specificity to CHODL protein (Supplementary Fig. S2 ). The expression levels of CHODL protein in lung cancer were significantly higher than those in testis.
We also evaluated CHODL staining in lung cancers and adjacent normal lung tissues, and confirmed CHODL protein to be positively stained in the majority of NSCLC tissues, but not in their corresponding normal lungs (Fig. 2C) .
Furthermore, CHODL protein was hardly detectable in benign lung disease of emphysema (Supplementary Fig. S3 ). Table 1B) . Among those parameters, strong CHODL-positivity, elderly, male gender, non-adenocarcinoma histology, advanced pT stage and advanced pN stage were significantly associated with poor prognosis. In multivariate analysis of prognostic factors, CHDOL-positivity, age, larger tumor size and lymph node metastasis were significant and independent prognostic factors for NSCLC patients.
Association of CHODL protein expression
Growth-promoting effect of CHODL. Using siRNA oligonucleotides for
CHODL, we attempted to knock down the expression of endogenous CHODL in lung cancer cell lines SBC-5 and NCI-H2170, which showed high levels of endogenous CHODL expression. Two CHODL-specific siRNAs (si-CHODL-#A and si-CHODL-#B) significantly suppressed expression of CHODL transcripts compared with control siRNAs (si-LUC and si-SCR) (Fig. 3A) . MTT and colony 3B and 3C; Supplementary Fig. S4) .
To further disclose a potential role of CHODL in tumorigenesis, we prepared plasmids designed to express either CHODL (pcDNA3.1/myc-His vector) or mock vector, and transfected them into COS-7, LC319 and BEAS-2B cells which scarcely expressed endogenous CHODL. Cells that transiently expressed exogenous CHODL revealed significant growth promotion compared with the mock-transfected cells (Figs. 3D and 3E ).
Enhanced cell invasion by CHODL. Since strong expression of CHODL in
NSCLC tissues was associated with poor prognosis of patients, we next examined a possible role of CHODL in cellular invasion by Matrigel assays using COS-7, LC319 and BEAS-2B cells. Transfection of CHODL cDNA into either of the cells significantly enhanced their invasive activity (Figs. 4A-4C ). This result also suggests that CHODL could contribute to the more malignant phenotype of cells. In this study, we demonstrated that CHODL was expressed only in testis among the 23 normal tissues examined and was highly expressed in surgically resected samples from NSCLC patients, indicating CHODL to be a typical To date, several prognostic biomarkers for lung cancer were reported, however, it is difficult to measure the malignant level of tumors in individual patients using only a single marker. To quantitatively predict the prognosis of NSCLC patients who had undergone curative surgery, we next attempted combined assays as a pilot study using the positivity data of CHODL and the available data of 2 other prognostic biomarkers for NSCLC (FGFR1OP and DLX5) which had been previously identified by our group using the same set of lung cancer tissues used in this study (23, 25) . NSCLC patients were divided into four groups; (group-1) all three markers were scored as strong positive in each patient, (group-2) either of two markers were strong positive, (group-3) either of one marker was strong positive, and (group-4) no marker was strong positive. There is a significant correlation between the increased number of strong positive markers and poorer prognosis of NSCLC patients Supplementary Fig. S5) . Although further screening and validation analyses that determine the best combination of promising prognostic biomarkers providing the best separation of long survivors and short ones are necessary, the results demonstrate that this type of diagnostic approach combined with more quantitative scoring system of immunohistochemical staining may be a useful and practical index in the clinic for application of adjuvant therapy to the patients who are likely to have poor prognosis after surgery.
Discussion
In summary, we have shown that over-expressed CHODL is likely to be one of essential contributors to a growth-promoting pathway and to aggressive features of lung cancers. CHODL is a possible prognostic biomarker in the clinic. 
